MAB-CHMINACA

synthetic cannabinoid

Also Known As:

ADB-CHMINACA; N-(1'-(aminocarbonyl)-2',2'-dimethylpropyl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - Indazoles: 179
        MAB-CHMINACA: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indazoles: 179
      - MAB-CHMINACA: 2

Experts

1.	Gonmori, Kunio: 1 article (02/2018)
2.	Hasegawa, Koutaro: 1 article (02/2018)
3.	Minakata, Kayoko: 1 article (02/2018)
4.	Nozawa, Hideki: 1 article (02/2018)
5.	Suzuki, Osamu: 1 article (02/2018)
6.	Watanabe, Kanako: 1 article (02/2018)
7.	Yamagishi, Itaru: 1 article (02/2018)
8.	Bailey, Blake C: 1 article (05/2016)
9.	Eustice, Eric R: 1 article (05/2016)
10.	Kacinko, Sherri: 1 article (05/2016)

Related Diseases

1.	Seizures (Absence Seizure) 05/01/2016 - "This case series describes 11 patients exposed to the synthetic cannabinoid, MAB-CHMINACA who presented to an emergency department with life-threatening toxicity including obtundation, severe agitation, seizures and death. "
2.	Poisoning 02/01/2018 - "An autopsy case in which the cause of death was judged as drug poisoning by two synthetic cannabinoids, including MAB-CHMINACA, was investigated. "

Related Drugs and Biologics

1.	Cannabinoids